Latanoprost

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michael Coote, MB, BS, FRANZCO, GAICD, of Melbourne Eye Specialists, presents positive safety and efficacy data for PA5108, an ocular implant for the treatment of glaucoma.

Once-daily dosing of NCX 470 demonstrated noninferiority compared with latanoprost in lowering IOP in patients with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc clinical trial.

TC-002, a latanoprost ophthalmic solution, met all primary and secondary endpoints in the phase 3 CLEAR pivotal trial, according to a press release from TearClear.

TearClear has initiated a phase 3 trial evaluating TC-002, a preservative-free latanoprost ophthalmic solution, in patients with glaucoma, according to a press release.

Roclanda has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency in Great Britain, according to a press release from Aerie Pharmaceuticals.

TearClear has appointed Stuart Raetzman as interim CEO and is preparing for a pivotal study on proprietary latanoprost for glaucoma treatment, according to a press release.

If glaucoma is diagnosed early, treatment for the disease can be delayed, as the treatment effect is usually modest and the patient has time to be treated at a later point.

The European Commission has granted marketing authorization for Roclanda to reduce IOP in adults with primary open-angle glaucoma or ocular hypertension, according to a press release from Aerie Pharmaceuticals.

TearClear and the FDA have completed a pre-investigational new drug meeting regarding development of and clinical study design for the company’s preservative-free multidose latanoprost formulation for glaucoma.

Dry eye disease and glaucoma both increase in prevalence with age. They are also commonly present in the patient who presents for cataract surgery.